March 24 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® ANNOUNCES FAVOURABLE AWARE-1 SAFETY UPDATE
* ONCOLYTICS BIOTECH - COHORT 1 SHOWED WIDESPREAD VIRAL REPLICATION IN MAJORITY TUMORS WITH CREATION OF PRO-INFLAMMATORY EFFECT IN TUMOR MICROENVIRONMENT
* ONCOLYTICS BIOTECH INC - NO NEGATIVE EFFECTS TO HEALTHY TISSUE WERE NOTED IN STUDY
* ONCOLYTICS BIOTECH - SAFETY COMMITTEE APPROVED AMENDMENT OF STUDY TO LOWER DOSE OF TECENTRIQ TO BE CURRENTLY APPROVED BREAST CANCER DOSE OF 840MG
* ONCOLYTICS BIOTECH INC - STUDY WILL CONTINUE TO ENROLL PATIENTS